| Name | Title | Contact Details |
|---|---|---|
Amy Garabedian |
General Counsel and Corporate Secretary | Profile |
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide.
We are a biopharmaceutical company focused on accelerating biologics and small molecules through clinical development that have the potential to improve patient lives. We are a team of seasoned pharmaceutical and start-up professionals with an extensive track record of success. Our expertise is in fast, efficient and high quality drug development. Whether developing a reformulated product or a new chemical entity, our management team has expertise to identify regulatory strategies to expedite the path to approval through efficient clinical programs.
Mixture Sciences Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Access Biologicals is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioMimetic Therapeutics is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.